DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
DaVita Inc. (DVA) reported trailing twelve months (TTM) revenue of $13.64B as of December 2025, which represents a 6.5% increase year-over-year. The company's operating margin has contracted to 15.2% from 17.2% a year ago. In terms of profitability, DVA generated $746.80M in net income. Valuation-wise, the stock trades at a P/E ratio of 13.4x and a Price-to-Sales (P/S) ratio of 0.7x. The company generated $395.30M in free cash flow over the last twelve months, indicating its ability to reinvest in growth or return capital to shareholders. Data based on the most recent quarterly reports.
Quarterly standardized metrics.
Stock price and market valuation
Top-line sales performance
EBITDA and Net Income trends
Price-to-earnings and price-to-sales ratios
Free cash flow generation
Operating and net margin percentages
